22.19 0.00 (0.00%)
After hours: 4:43PM EDT
|Bid||21.78 x 800|
|Ask||23.50 x 800|
|Day's Range||22.01 - 23.73|
|52 Week Range||16.33 - 35.99|
|Beta (3Y Monthly)||3.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.75|
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, presented new data from three of its programs, including the company’s first data on complex edits, at the 26th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), in Lausanne, Switzerland. “We are extremely pleased to present an outstanding compilation of data today reflecting progress in our preclinical genome editing programs,” said Intellia President and Chief Executive Officer John Leonard, M.D. “We showed that we can efficiently introduce complex edits in mice by inserting genes to express proteins that are deficient in some genetic diseases.
NEW YORK, Oct. 10, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On October 4, Sangamo Therapeutics (SGMO) stock ended the trading day at $14.81—down ~3.4% from the previous day’s close. The stock registered its 52-week high of $27.50 on February 22. Sangamo Therapeutics reported its 52-week low of $11.30 on October 26, 2017. Currently, the stock is trading ~5.5% lower than its 50-day moving average of $15.68 and ~9% lower than its 200-day moving average of $16.27.
CAMBRIDGE, Mass., Sept. 24, 2018-- Intellia Therapeutics, Inc., a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate in the ...
In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million compared to $5.9 million in the second quarter of 2017. Intellia Therapeutics’ collaboration agreement with Regeneron Pharmaceuticals (REGN) primarily contributed to the increase in its collaboration revenue in the second quarter. In the first half of 2018, Intellia Therapeutics reported net collaboration revenue of $15.1 million compared to $12.1 million in the first half of 2017.
Intellia Therapeutics is a genome-editing company that’s currently focused on the development of curative therapies utilizing the CRISPR/Cas9 system. In August, Intellia Therapeutics presented data from a study in which a humanized mouse model of hereditary transthyretin amyloidosis demonstrated a reduction in amyloid deposition in multiple tissues after the administration of a single dose of lipid nanoparticles. Of the seven analysts tracking Intellia Therapeutics in September, three have recommended “strong buys,” while three have recommended “buys” on its stock.
In the second quarter, Editas Medicine (EDIT) reported revenues of $7.3 million from collaborations and other R&D (research and development) activities. In comparison, the company’s revenues reached $3.1 million in the second quarter of 2017.
The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells University of California/University of Vienna/Dr. ...
The U.S. Court of Appeals for the Federal Circuit affirmed the validity of the Harvard and MIT patents, rejecting a challenge brought by a rival team of researchers associated with the University of California at Berkeley and University of Vienna in Austria. Shares of Cambridge, Massachusetts-based Editas Medicine Inc, a biotechnology company that licenses Harvard and MIT's CRISPR-related patents, rose nearly 7 percent after the ruling before giving back most of those gains and was up 1 percent at $30.56.
In the second quarter, CRISPR Therapeutics reported net income and EPS (earnings per share) of -$38.4 million and -$0.82, respectively, compared to net income and EPS of -$22.3 million and -$0.56 in the second quarter of 2017. In the first half of the year, CRISPR Therapeutics reported net income and EPS of -$66.7 million and -$1.44, respectively, compared to -$43.8 million and -$1.10 in the first half of 2017.
CRISPR Therapeutics (CRSP) has already obtained approval for clinical trial applications (or CTA) across multiple countries for its CTX001, an investigational autologous gene-edited hematopoietic stem cell therapy for the treatment of individuals with severe hemoglobinopathies. CRISPR Therapeutics and its partner, Vertex Pharmaceuticals, obtained CTA approvals for the evaluation of the therapy for the treatment of beta-thalassemia and sickle cell disease.
The three leading CRISPR gene-editing companies announced first-half 2018 earnings last month, and received a boost on the final day of August.
Over the last six years, a small group of scientists working at different institutes have made incredible progress in a revolutionary new field called gene editing. Gene editing is just what it sounds like. It’s the changing — or “editing” — of an organism’s genes to produce a desired outcome.
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, presented data from studies demonstrating a decrease in amyloid deposition in multiple tissues of a humanized mouse model of hereditary transthyretin amyloidosis (ATTR) after a single dose of lipid nanoparticles (LNPs). The company also presented non-human primate (NHP) data from initial studies showing a therapeutically meaningful level of TTR protein reduction that correlated with robust and significant liver editing following a single administration of LNPs.
NEW YORK, Aug. 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of IQVIA ...
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 8.77% and 20.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Continued to progress lead in vivo program in transthyretin amyloidosis targeting submission of an Investigational New Drug application by the end of 2019 Announced first wholly owned ex vivo T cell receptor ...
The stock prices of gene-editing companies like CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA) saw a sharp correction in July. These companies are focused on clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology, and have fallen on concerns stemming from a recently published study.
How Intellia Therapeutics quickly became one of the top gene-editing biotech stocks on the market.
These companies are reeling from last week's study showing potentially negative effects from their gene-engineering tools.
NEW YORK, NY / ACCESSWIRE / July 17, 2018 / Shares of Intellia Therapeutics were in the red on Monday along with other CRISPR gene editing companies as a study found that the technique can damage DNA. CRISPR Therapeutics as well as Editas Medicine Inc. also saw losses. Dr. Reddy’s Laboratories saw losses after receiving a court order that prevents the company from selling Buprenorphine and Naloxone Sublingual Film.
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on ICPT sign up now at www.wallstequities.com/registration. Biotech firms differ from conventional drug makers in that they utilize natural ingredients, as opposed to synthetic ones.